Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in AIDS-Associated Kaposi's Sarcoma
NCT01057121Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2010
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in Kaposi sarcoma (KS), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose of Lenalidomide at 28 days and Tumor Response Rate. Started Aug 2010; status: completed.
02
Drugs
lenalidomide
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT01057121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01057121.